Highbridge Capital Management, LLC filed Amendment No. 2 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 1,454,400 shares of INmune Bio, Inc. common stock issuable upon exercise of warrants held by Highbridge-managed funds.
Key Highlights
- Beneficial ownership: Highbridge Capital Management, LLC reported aggregate beneficial ownership of 1,454,400 shares of INmune Bio common stock.
- Ownership percentage: The 1,454,400 shares represent 4.98% of the class, based on 27,753,789 shares outstanding as of August 6, 2026.
- Source of shares: All reported shares reflect common stock issuable upon exercise of warrants directly held by the Highbridge Funds, not shares held outright.
- Sole voting and dispositive power: Highbridge reported sole voting power and sole dispositive power over all 1,454,400 shares, with zero shared voting or dispositive power.
- Triggering event: The event requiring this filing occurred on September 30, 2026.
- Reporting person type: Highbridge is classified as an investment adviser (IA) and other (OO), organized as a Delaware limited liability company.
Highbridge Capital Management Discloses Warrant-Linked Position in INmune Bio
According to the filing, Highbridge Capital Management, LLC, a Delaware limited liability company and investment adviser to certain funds and accounts referred to as the "Highbridge Funds," filed Amendment No. 2 to Schedule 13G with respect to common stock, par value $0.001 per share, of INmune Bio, Inc. (NASDAQ:INMB), a Nevada corporation. The filing states that the securities reported consist entirely of shares issuable upon exercise of warrants directly held by the Highbridge Funds, not shares of common stock held outright.
The filing reports 1,454,400 shares beneficially owned, representing 4.98% of the class. According to the filing, that percentage was calculated using an aggregate of 27,753,789 shares of common stock outstanding as of August 6, 2026, as reported in INmune Bio's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2026, and assumes the exercise of the warrants held by the Highbridge Funds. The filing notes that Item 5 applies, designating this as ownership of 5 percent or less of a class.
The filing states that the Highbridge Funds "have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein." Highbridge's principal business office is listed as 390 Madison Avenue, 28th Floor, New York, NY 10017. The statement was signed by Kirk Rule, Executive Director, on November 16, 2026. The filing includes a certification that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."
What Was Disclosed
Highbridge Capital Management, LLC filed Amendment No. 2 to Schedule 13G disclosing beneficial ownership of 1,454,400 shares of INmune Bio common stock, all issuable upon warrant exercise, representing 4.98% of the class as of the September 30, 2026 triggering event.




Please wait processing your request...